Pathogenesis and treatment of gastric carcinoma: "An up-date with brief review"

Journal of Cancer Research and Therapeutics

Volumn 2, Issue 4, 2006, Pages 196-199

  Khan, Farhat ^a,b   Shukla, Aditya ^a  

^a ADVANCED MEDICAL AND DENTAL INSTITUTE   (Malaysia)

^b NONE   (Malaysia)

Author keywords

Gastric cancer; Management; Pathogenesis

Indexed keywords

EID: 33846599252     PISSN: 09731482     EISSN: 09731482     Source Type: Journal    
DOI: 10.4103/0973-1482.29830     Document Type: Review

References (35)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. Eur J Cancer 2001;37:S4-66.
2. Parkin DM. International variation. Oncogene 2004;23:6329-40.
3. Ries LA, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK. SEER cancer statistics review 1973-1994, National cancer Institute, NIH Publication No. 97-2789. Department of health and human services: Bethesda; 1997.
4. Faivre J, Forman D, Esteve J, Gatta G. Survival of patients with esophageal and gastric cancers in Europe. Eur J Cancer 1998;34:2167-75.
5. Berrino F, Capocaccioa R, Esteve J. Survival of cancer patients in Europe. The Eurocare -2 study. IARC Scientific publication No 151. IARC: Lyon; 1999.
6. Strumylaite L, Zickute J, Dudzevicius J, Dregval L. Salt preserved foods and risk of gastric cancer. Medicina (Kaunas) 2006;42:164-70.
7. Correa P, Human Gastric Carcinogenesis: A multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer epedemiology and prevention. Cancer Res 1992;52:6735-40.
8. Kountouras J, Zavos C, Chatzo PD. New Concepts of molecular biology on gastric careinogenesis. Hepatogastroentesology 2005;52:1305-12.
9. Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H. Search for new biomarkers of gastric cancer through serial analysis of gene expression (SAGE) and its clinical implications. Cancer Science 2004,95:385-92.
10. Edwin PM, Jansen. Optimal loco regional treatment in gastric cancer. JCO 2005. p. 4509-17.
11. Karpeh MS, Kelsen DP, Tepper JE. Cancer of the stomach. Principles and Practice of Oncology. De Vita VT, Helman S, Rosemberg SA, editors. Lippincott Williams and Wilkins: Philadelphia, PA; 2001. p. 1092-126.
12. Muruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limit of radicality. World J Surg 1987;11:418-25.
13. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient's survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized clinical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522-30.
14. Bunt TM, Bonenkamp HJ, Hermans J, van de Velde CJ, Arends JW, Fleuren G, et al. Factors influencing non-compliance and contamination in a non-randomized trial of 'western' (R1) versus 'Japanese' (R2) type surgery in gastric cancer. Cancer 1994;73:1544-51.
15. Hartgrink HH, et al. Extended lymph node dissection of gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. JCO 2004. p. 2069-77.
16. Wei- Jei Lee. No therapeutic effect of extended lymph node dissection for gastric cancer. JCO 2005. p. 1592-3.
17. Chipponi J, Huguier M, Pezet D, Basso N, Hay JM, Quandalle P, et al. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg 2004;187:440-5.
18. Neri B, Cini G, Andreoli F, Boffi B, Francesconi D, Mazzanti R, et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer 2001;84:878-80.
19. Chang HM, Jung KH, Kim TY, Kim WS, Yang HK, Lee KU, et al. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer. Ann Oncol 2002;13:1779-85.
20. Macdonald JS, Fleming TF, Peterson RF, Berenberg JL, McClure S, Chapman RA, et al. Adjuvant chemotherapy with 5-FU, adriamycin and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995;488-94.
21. Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995;13:2757-63.
22. Coombes RC, Schein PS, Chilvers CE, Wils J, Beretta G, Bliss JM, et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 1990;8:1362-9.
23. Bajetta E, Buzzoni R, Mariani L, Beretta E, Bozzetti F, Bordogna G, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002;13:299-307.
24. Grau JJ, Estape J, Alcobendas F, Pera C, Daniels M, Teres J. Positive results of adjuvant mitomycin-C in resected gastric cancer: A randomised trial on 134 patients. Eur J Cancer 1993;29A:340-2.
25. Cirera L, Balil A, Batiste-Alentorn E, Tusquets I, Cardona T, Arcusa A, et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999;17:3810-5.
26. Neri B, Cini G, Andreoli F, Boffi B, Francesconi D, Mazzanti R, et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5 year follow-up. Br J Cancer 2001;84:878-80.
27. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
28. Macdonald JS, Smalley SR, Benedetti J, Este N, Haller DG, Ajani J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival and overall survival in resected adenocarcinoma of the stomach and gastroesophageal junction: Update of the results of Intergroup Study INT-0116, Proc GI Can Symp 2004;1.
29. Lionel Lim, et al. Adjuvant therapy in gastric cancer. JCO 2005. p. 6220-32.
30. Allum W, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomized, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc Am Soc Clin Oncol 2003;22.
31. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al. Multi-institutional trial of Pre-operative Chemoradiotherapy in Patients with Potentially respectable gastric cancinoma. J Clin Oncol 2004;22:2774-80.
32. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
33. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al, Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004.
34. Monig SP, Baldus SE, Hennecken JK, Spiecker DB, Grass G, Schneider PM, et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001;39:597-602.
35. Chiung-Nien Chen, et al. Gene expression profile predicts patient survival of gastric cancer after surgical resection. JCO 2005. p. 7286-95.